Generic entry timeline

Azelex generics — when can they launch?

Azelex (AZELAIC ACID) · Leo Pharma As · 4 active US patents · 0 expired

Earliest patent expiry
2027-09-18
1 year remaining
Full patent estate to
2029-02-28
complete protection through 2029
FDA approval
1995
Leo Pharma As

Where Azelex sits in the generic timeline

Imminent generic cliff: earliest active US patent for Azelex expires in 2027 (~1 year from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Formulation — 2 patents
  • Method of Use — 2 patents

FDA U-codes carved out by Azelex patents

Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.

U-codeDescription
U-1796(no description)

Sample patent estate

Showing 4 of 4 active US patents. View full estate on the Azelex drug page →

  • US7700076 Formulation · expires 2027-09-18
    This patent protects a formulation of an alcohol-free cosmetic or pharmaceutical foam composition that enhances skin penetration.
    USPTO title: Penetrating pharmaceutical foam
  • US10117812 Method of Use · expires 2027-10-18
    This patent protects a foamable composition for a pharmaceutical or cosmetic product, specifically a vehicle combining a polar solvent and a hydrophobic carrier.
    USPTO title: Foamable composition combining a polar solvent and a hydrophobic carrier
  • US9265725 Formulation · expires 2027-12-08
    This patent protects a foamable pharmaceutical carrier for delivering a dicarboxylic acid or ester as a benefit agent.
    USPTO title: Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
  • US9211259 Method of Use · expires 2029-02-28
    This patent protects a therapeutic kit that releases a foam containing an antibiotic agent, such as Foamix Pharmaceuticals' Azelex, for safe and effective use.
    USPTO title: Antibiotic kit and composition and uses thereof

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on Azelex — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →